Edition:
India

Enlivex Therapeutics Ltd (ENLV.OQ)

ENLV.OQ on NASDAQ Stock Exchange Capital Market

34.70USD
18 Sep 2019
Change (% chg)

$0.90 (+2.66%)
Prev Close
$33.80
Open
$34.16
Day's High
$34.70
Day's Low
$34.16
Volume
513
Avg. Vol
3,873
52-wk High
$35.66
52-wk Low
$6.32

Summary

Name Age Since Current Position

Shai Novik

2014 Executive Chairman of the Board

Shmuel Hess

2018 Chief Executive Officer

Shachar Shlosberger

Chief Financial Officer

Dror Mevorach

Chief Scientific & Medical Officer

Odelia Ben-Shitrit

Head of Clinical Operations

Adi Tabib

Head Of CMC

Michel Habib

52 2017 Director

Baruch Halpert

52 2017 Director

Gili Hart

2014 Director

Abraham Havron

71 2014 Director

Bernhard Kirschbaum

58 2018 Director

Hyun Gyu Lee

2017 Director

Sangwoo Lee

2017 Director

Biographies

Name Description

Shai Novik

Mr. Shai A. Novik is Executive Chairman of the Board of the Company since 2014. Mr. Novik founded PROLOR Biotech in 2005, and served as its President until 2014. PROLOR Biotech was listed on the NYSE in 2010 and was sold in 2013, the second largest biotech exit ($560 million) in the history of Israeli biotech. Mr. Novik previously served as Chief Operating Officer and Head of Strategic Planning of THCG, Inc., a technology and life sciences investment company. THCG was a portfolio company of Greenwich Street Partners, one of the largest U.S. private equity funds. THCG’s own portfolio included several life sciences and medical devices companies. Mr. Novik received his M.B.A, with distinction, from the Cornell University.

Shmuel Hess

Mr. Shmuel Hess Ph.D., is Chief Executive Officer of the Company since Nov 1, 2018. Dr. Hess received his Ph.D. in Pharmaceutical Science from the Hebrew University, Israel and was a research fellow at Harvard-MIT Health Sciences and Technology (HST). Prior to joining Enlivex, Dr. Hess served as the CEO of Valin Technologies from its inception in 2009 until and oversaw the execution of the company activities and its achievements, including the development, technology transfer, establishment of cGMP manufacturing facilities for several biosimilars, the first of which has received marketing approval in China; and the in-licensing and acquisition of three early stage innovative drugs. Formerly, Dr. Hess served in global operations at Scigen LTD (NASDAQ: VBIV). Dr. Hess is the inventor of multiple patents and author of numerous publications in peer reviewed scientific journals.

Shachar Shlosberger

Ms. Shachar Shlosberger is Chief Financial Officer of the Company. Former Prolor Biotech Ltd Finance Director where she was responsible for the overall financial operations in Israel and US. Shachar is a Certified Public Accountant and holds a M.B.A. in Accounting and Business Administration.

Dror Mevorach

Mr. Dror Mevorach is Chief Scientific & Medical Officer of the Company. He is a leading scientist on the removal of apoptotic cells and the Co-Chaired several Apoptotic Cell Recognition and Clearance at Gordon Research Conference and in international meetings. Prof. Mevorach is currently the Chairman of Medicine, and the Director of the Rheumatology Research Centre of Hadassah-Hebrew University Hospital and School of Medicine in Jerusalem. Prof. Mevorach published more than 100 scientific papers and is a frequent lecturer at international conferences. Prof. Mevorach earned his M.D. (Cum Laude) from The Technion – Israel Institute of Technology in Haifa, Israel, and was a fellow at the Hospital for Special Surgery and Cornell Medical School, NY.

Odelia Ben-Shitrit

Mr. Odelia Ben-Shitrit is Head of Clinical Operations of the Company. He has Over 20 years of experience in clinical trials and operational management in various therapeutic areas. Former Teva and PAREXEL clinical leader.

Adi Tabib

Ms. Adi Tabib is Head Of CMC of the Company. She has been serving as the Head of Development and Manufacturing at Enlivex since 2007. Adi researched her M.SC.’s thesis at Prof. Mevorach’s laboratory.

Michel Habib

Mr. Michel Habib is Director of the Company since 2017. Michel was the co-founder and managed Agate Medical Investments and Agate MaC VC funds, with over $100 million under management. His portfolio companies have attracted investments from leading global and Chinese companies, including Boston Scientific, Johnson & Johnson, Medtronic, Haisco, Longtech, Xio. Currently Mr. Habib serves on the board of several investment companies and startups, including Xenia Ventures, Kahr Medical (Chairman), Enlivex, Cellcure, Bioprotect and Ornim Medical. Prior to that he managed Matar Capital Advisors, a venture boutique. Michel Habib served for nearly four years as Elron’s Business Development Director, focusing on the Medical Devices sector. Prior to Elron, he established and managed the investment banking activity of ING Barings in Israel. Formerly, he served as Vice President Investment Banking at Cukierman & Co. where he led private placements and IPOs in Europe. During the 90’s Mr. Habib served as a diplomat in Israel’s foreign service, where he served as Economic Consul in Boston, and earlier as the first Commercial Attache to Seoul, South Korea. As Navy Officer (Captain Res.) in the IDF, he was involved in the development of advanced Naval warfare systems for the Navy’s elite unit. Mr. Habib holds an Aeronautical Engineering degree from the Technion-Israel Institute of Technology, and is a graduate from Harvard Law School Executive Program On Negotiation (PON). He is a graduate from the foreign service cadet school, and member of the Technion Alumni “100 Club”.

Baruch Halpert

Mr. Baruch Halpert is Director of the Company since 2017. With more than 20 years of experience in venture capital and private equity as an entrepreneur, corporate finance advisor, senior executive and an investor, Baruch has developed a large network of contacts across the globe. Since 2010, Baruch and has been involved in turn arounds through active management and private equity investments of high yield opportunities. In this capacity, Baruch is active in investing in companies with annual revenues of at least USD 100 million in special situations and took part in the successful turnarounds of, inter alia, Hemaclear (www.hemaclear.com), Apnano (www.nisusacorp.com) and HBL (www.hbl.co.il). Early in his career, Baruch was active in oil and gas exploration in Israel. In that capacity he obtained, developed and sold the rights to an Israeli oil and gas exploration license, the Megiddo Prospect, to Ultra Petroleum (AMEX: UPL). In 1997, Baruch founded E*TRADE Israel (www.etrade.com). Obtaining a license from E*TRADE, Baruch put together a core management team and headed several successful rounds of financing. Following E*TRADE, Baruch was Head of Corporate Finance at Fantine Capital. Baruch holds an LLB Degree (Hons.) from Reading University, United Kingdom.

Gili Hart

Ms. Gili Hart is Director of the Company since 2014. She previously held various positions in PROLOR Biotech and led the pre-clinical, clinical and pharmacological activities there from 2008 until her move to Mitoconix Bio, a biopharmaceutical company developing disease modifying therapies addressing unmet medical needs by improving mitochondrial health, where she serves as Chief Executive Officer. Dr. Hart was a research fellow in the Immunology Department of Yale University in Connecticut from 2005 to 2007 and a research fellow at the Immunology Department of the Weizmann Institute of Science in Israel. Dr. Hart received her Ph.D. with distinction from the Immunology Department of the Weizmann Institute of Science in immunology, and a M.S. degree in Biotechnology Engineering, summa cum laude, from the Technion Institute in Israel. Dr. Hart has published numerous papers and patents, in each case focusing on autoimmunity disease and immune system activation.

Abraham Havron

Dr. Abraham (Avri) Havron, Ph.D., is Director of the Company since 2014. He has served as the CEO of PROLOR Biotech Inc. from 2005 through 2013. Dr. Havron is a 35-year veteran of the biotechnology industry and was a member of the founding team and Director of Research and Development of Interpharm Laboratories (a subsidiary of Serono) from 1980 to 1987, and headed the development of the multiple sclerosis drug REBIF, with current sales of more than $1.5 billion annually. Dr. Havron served as Vice-President Manufacturing and Process-Development of BioTechnology General Ltd., from 1987 to 1999; and Vice President and Chief Technology Officer of Clal Biotechnology Industries Ltd. from 1999 to 2003. Dr. Havron’s managerial responsibilities included the co-development of several therapeutic proteins and other bio-pharmaceuticals currently in the market, including recombinant human growth hormone (BioTropin), recombinant Hepatitis B Vaccine (Bio-Hep-B), recombinant Beta Interferon (REBIF), recombinant human insulin and hyaluronic acid for ophthalmic and orthopedic applications. Dr. Havron earned his Ph.D. in Bio-Organic Chemistry from the Weizmann Institute of Science, and served as a Research Fellow in the Harvard Medical School, Department of Radiology.

Bernhard Kirschbaum

Dr. Bernhard Jurgen Kirschbaum, Ph.D., is Director of the Company since 2018. He has served as Executive Vice President & Member of the Board at Merck Serono, Head of Global Research & Early Development reporting to the CEO of Merck Serono. He led a global team of more than 1,200 employees, with a 400 million Euro annual budget. Mr. Kirschbaum has significant expertise in a broad range of disease areas, including rheumatology/immunology, thrombosis, cardiometabolic diseases, oncology and neurology. He has successfully participated in the profiling of several drugs in their course to the market or during market expansion, including Arava, Velcade, Lovenox, Erbitux and Avelumab. Mr. Kirschbaum led drug portfolio re-allocation with focus on the therapeutic areas: oncology, neurodegenerative diseases (MS, Alzheimers, Parkinsons), autoimmune and inflammatory Diseases. Mr. Kirschbaum has also been involved in research activities with respect to fertility, mainly focusing on embryo technologies. He implemented the new Merck Serono research organization, including an exploratory medicine department and all non-clinical development functions (toxicology, general & safety pharmacology, CMC development and DMPK). Previously, Mr. Kirschbaum was Vice President Discovery Research, Global Head of Thrombosis and Angiogenesis at Sanofi-Aventis; Vice President, Drug Innovation and Approval at Sanofi-Aventis; and Head of the Center for Applied Genomics (TCAG) at HMR. Mr. Kirschbaum earned his Ph.D. in biochemistry, summa cum laude, from the University of Konstanz, Germany; was a postdoctoral fellow with Dr. R.G. Roeder, at the Rockefeller University in New York, and a Research Associate with Dr. M. Buckingham at Institut Pasteur in Paris.

Hyun Gyu Lee

Mr. Hyun Gyu Lee, Ph.D., M.D. is Director of the Company since 2017. Mr. Lee is the Executive Director, Investment Division, of Korea Investment Partners Co., Ltd., the largest venture capital fund in Korea. He was previously Research Assistant Professor with the Department of Microbiology and Immunology, Institute for Immunology and Immunological Diseases, Yonsei University, College of Medicine in Seoul, Korea. He received his Ph.D. in Immuno-Pathology from the Seoul National University, College of Medicine in Seoul, Korea, and his M.D. degree from Seoul National University, College of Medicine in Seoul, Korea.

Sangwoo Lee

Mr. Sangwoo Lee is Director of the Company. He is an Executive Director of the Investment Department & Head of U.S. Branch at Korea Investment Partners Co. Ltd., the largest venture capital fund in Korea. He is responsible for sourcing and evaluation of start-up companies, investment and participation in business development and growth expansion of the fund’s investments in the United States and Europe. Previously, Mr. Lee was General Manager of the MSC Department at Samsung Electronics, responsible for strategic and business planning; and Vice President, CTO & Foreign Marketing Group Leader at Polidigm Co. Ltd. Mr. Lee received his B.Sc. and M.Sc. from Seoul National University, Department of Control and Instrumentation.